Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ABBOTT ULTANE INHALATION ANESTHETIC SHIPMENTS TO BEGIN BY END OF JUNE; PHASE IV NEPHROTOXICITY STUDIES TO FOCUS ON COMPOUND A, LOW GAS FLOW RATES

Executive Summary

Abbott will begin shipping the inhaled anesthetic Ultane (sevoflurane) by the end of June, the company indicated following FDA approval of the drug June 7 for induction and maintenance of general anesthesia in adult and pediatric patients undergoing inpatient and outpatient surgery.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS026330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel